Ross A. Miller - Fanwood NJ Andrew S. Thompson - Mountainside NJ Raman K. Bakshi - Edison NJ Edward G. Corley - Old Bridge NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07J 900
US Classification:
552542, 552636, 540 2, 540106
Abstract:
The instant invention involves a process for oxidizing compounds containing an allylic group, i. e. those containing an allylic hydrogen or allylic alcohol group, to the corresponding enones, using a ruthenium-based catalyst in the presence of a hydroperoxide. Particularly, -5-steroidal alkenes can be oxidized to the corresponding -5-7-keto alkenes.
Intermediates Useful In A Process For Synthesizing Cox-2 Inhibitors
Edward G. Corley - Old Bridge NJ Ian W. Davies - Princeton NJ Robert D. Larsen - Bridgewater NJ Philip J. Pye - Guttenberg NJ Kai Rossen - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07C21100
US Classification:
564509
Abstract:
The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1##.
Edward G. Corley - Old Bridge NJ Ian W. Davies - Princeton NJ Robert D. Larsen - Bridgewater NJ Philip J. Pye - Guttenberg NJ Kai Rossen - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A01N 4340 C07D21130 C07D21178 C07D21172 C07D21362
US Classification:
514334
Abstract:
The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1##.
Process For Deblocking N-Substituted .Beta.-Lactams
Newton L. Abramson - Edison NJ Sandor Karady - Mountainside NJ Edward G. Corley - Old Bridge NJ Leonard M. Weinstock - Belle Mead NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07D20504 C07D40304 C25B 302 C25B 304
US Classification:
204 59R
Abstract:
This invention relates to a process for preparing. beta. -lactams by electrochemically deblocking N-substituting. beta. -lactams using anodic oxidation.
Andrew S. Thompson - Mountainside NJ Edward G. Corley - Old Bridge NJ Martha Huntington - Edison NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07C 1207
US Classification:
585359
Abstract:
An improved synthesis of cyclopropylacetylene involving cyclization of 5-halo-1-pentyne in strong base is disclosed, and is useful for preparing compounds with a cyclopropylethynyl substituent, such as an intermediate for a highly potent HIV reverse transcriptase inhibitor or other pharmaceutically active compounds.
James D. Carroll - Carteret NJ David J. Mathre - Skillman NJ Edward G. Corley - Old Bridge NJ Andrew S. Thompson - Mountainside NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07F 502 C07D23502
US Classification:
546 13
Abstract:
Oxazaborolidine-borane complexes are prepared by adding a C. sub. 5-8 alkane, typically hexane, to an aged solution of oxazaborolidine and a source of borane such as borane-dimethyl sulfide or gaseous diborane to crystallize the oxazaborolidine complex.
Asymmetric Synthesis Of (-)6-Chloro-4-Cyclopropyl-Ethynyl-4-Trifluoromethyl-1,4-Dihydro-2H-3,1-B Enzoxazin-2-One
Andrew S. Thompson - Mountainside NJ Edward G. Corley - Old Bridge NJ Edward J. J. Grabowski - Westfield NJ Nobuyoshi Yasuda - Mountainside NJ
Assignee:
Merck & Co. Inc. - Rahway NJ
International Classification:
C07C21100 C07C 5116
US Classification:
564389
Abstract:
An improved synthesis of a highly potent HIV reverse transcription inhibitor is disclosed, involving an acetylide and a trifluoromethyl ketone which produces a chiral product in the presence of a chiral amino alcohol.
Asymmetric Synthesis Of (-)-6-Chloro-4-Cyclopropyl-Ethynyl-4-Trifluoromethyl-1,4-Dihydro-2H-3,1- Benzoxanzin-2-One
Andrew S. Thompson - Mountainside NJ Edward G. Corley - Old Bridge NJ Edward J.J. Grabowski - Westfield NJ Nobuyoshi Yasuda - Mountainside NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07C21100 C07C 5116
US Classification:
564321
Abstract:
An improved synthesis of a highly potent HIV reverse transcription inhibitor is disclosed, involving an acetylide and a trifluoromethyl ketone which produces a chiral product in the presence of a chiral amino alcohol.